Role of melatonin supplementation in neurodegenerative disorders

Frontiers in Bioscience - Landmark

Volumn 19, Issue 3, 2014, Pages 429-446

  Polimeni, Giovanni ^a   Esposito, Emanuela ^b   Bevelacqua, Valentina ^c,d   Guarneri, Claudio ^b   Cuzzocrea, Salvatore ^b  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c GARIBALDI HOSPITAL   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antioxidant; Dietary supplementation; Melatonin; Neurodegenerative disorders; Neuroprotection; Review

Indexed keywords

MELATONIN;

DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; HUMAN; REVIEW;

DIETARY SUPPLEMENTS; HUMANS; MELATONIN; NEURODEGENERATIVE DISEASES;

EID: 84904363476     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4217     Document Type: Review

References (185)

1. B. Halliwell: Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br J Exp Pathol 70, 737-57 (1989)
2. D. M. Guidot, J. E. Repine, A. D. Kitlowski, S. C. Flores, S. K. Nelson, R. M. Wright and J. M. McCord: Mitochondrial respiration scavenges extramitochondrial superoxide anion via a nonenzymatic mechanism. J Clin Invest 96, 1131-6 (1995)
3. M. K. Shigenaga, T. M. Hagen and B. N. Ames: Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A 91, 10771-8 (1994)
4. S. Cuzzocrea, C. Thiemermann and D. Salvemini: Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr Med Chem 11, 1147-62 (2004)
5. B. N. Ames: Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun, 7, 121-8 (1989)
6. F. Ng, M. Berk, O. Dean and A. I. Bush: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11, 851-76 (2008)
7. K. J. Davies: Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 50, 279-89 (2000)
8. M. E. Gotz, G. Kunig, P. Riederer and M. B. Youdim: Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63, 37-122 (1994)
9. D. X. Tan, L. C. Manchester, R. J. Reiter, W. B. Qi, M. Karbownik and J. R. Calvo: Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 9, 137-59 (2000)
10. R. J. Reiter: Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 79, C153-8 (1991)
11. A. Menendez-Pelaez, K. A. Howes, A. Gonzalez-Brito and R. J. Reiter: N-acetyltransferase activity, hydroxyindole-O-methyltransferase activity, and melatonin levels in the Harderian glands of the female Syrian hamster: changes during the light:dark cycle and the effect of 6-parachlorophenylalanine administration. Biochem Biophys Res Commun 145, 1231-8 (1987)
12. D. X. Tan, L. C. Manchester, R. J. Reiter, W. B. Qi, M. Zhang, S. T. Weintraub, J. Cabrera, R. M. Sainz and J. C. Mayo: Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1472, 206-14 (1999)
13. R. J. Reiter, D. X. Tan, J. Cabrera, D. D'Arpa, R. M. Sainz, J. C. Mayo and S. Ramos: The oxidant/antioxidant network: role of melatonin. Biol Signals Recept 8, 56-63 (1999)
14. J. Rosen, N. N. Than, D. Koch, B. Poeggeler, H. Laatsch and R. Hardeland: Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res 41, 374-81 (2006)
15. K. Manda, M. Ueno and K. Anzai: AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 42, 386-93 (2007)
16. D. X. Tan, L. C. Manchester, M. P. Terron, L. J. Flores and R. J. Reiter: One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 42, 28-42 (2007)
17. C. Tomas-Zapico and A. Coto-Montes: A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 39, 99-104 (2005)
18. R. M. Hagan and N. R. Oakley: Melatonin comes of age? Trends Pharmacol Sci 16, 81-3 (1995)
19. H. Tricoire, A. Locatelli, P. Chemineau and B. Malpaux: Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 143, 84-90 (2002)
20. D. C. Skinner and B. Malpaux: High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 140, 4399-405 (1999)
21. R. T. Cheung, G. L. Tipoe, S. Tam, E. S. Ma, L. Y. Zou and P. S. Chan: Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res 41, 337-43 (2006)
22. R. J. Reiter, D. X. Tan, W. Qi, L. C. Manchester, M. Karbownik and J. R. Calvo: Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept, 9, 160-71 (2000)
23. D. Melchiorri, R. J. Reiter, A. M. Attia, M. Hara, A. Burgos and G. Nistico: Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci 56, 83-9 (1995)
24. E. Sewerynek, D. Melchiorri, L. Chen and R. J. Reiter: Melatonin reduces both basal and bacterial lipopolysaccharide-induced lipid peroxidation in vitro. Free Radic Biol Med 19, 903-9 (1995)
25. D. X. Tan, B. Poeggeler, R. J. Reiter, L. D. Chen, S. Chen, L. C. Manchester and L. R. Barlow-Walden: The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett 70, 65-71 (1993)
26. G. R. Martinez, E. A. Almeida, C. F. Klitzke, J. Onuki, F. M. Prado, M. H. Medeiros and P. Di Mascio: Measurement of melatonin and its metabolites: importance for the evaluation of their biological roles. Endocrine 27, 111-8 (2005)
27. R. J. Reiter, D. X. Tan, E. Gitto, R. M. Sainz, J. C. Mayo, J. Leon, L. C. Manchester, Vijayalaxmi, E. Kilic and U. Kilic: Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol 56, 159-70 (2004)
28. E. Gitto, D. X. Tan, R. J. Reiter, M. Karbownik, L. C. Manchester, S. Cuzzocrea, F. Fulia and I. Barberi: Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 53, 1393-401 (2001)
29. F. Martinez-Cruz, J. M. Guerrero and C. Osuna: Melatonin prevents the formation of pyrrolized proteins in human plasma induced by hydrogen peroxide. Neurosci Lett 326, 147-50 (2002)
30. R. J. Reiter, D. X. Tan, L. C. Manchester and H. Tamura: Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J Physiol Pharmacol 58, 5-22(2007)
31. F. Radogna, M. Diederich and L. Ghibelli: Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol, 80, 1844-52 (2010)
32. A.Teixeira, M. P. Morfim, C. A. de Cordova, C. C. Charao, V. R. de Lima and T. B. Creczynski-Pasa: Melatonin protects against pro-oxidant enzymes and reduces lipid peroxidation in distinct membranes induced by the hydroxyl and ascorbyl radicals and by peroxynitrite. J Pineal Res 35, 262-8 (2003)
33. G. Ferry, C. Ubeaud, P. H. Lambert, S. Bertin, F. Coge, P. Chomarat, P. Delagrange, B. Serkiz, J. P. Bouchet, R. J. Truscott and J. A. Boutin: Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochem J 388, 205-15 (2005)
34. B. Claustrat, J. Brun and G. Chazot: The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9, 11-24 (2005)
35. R. J. Reiter: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12, 151-80 (1991)
36. J. Leon, G. Escames, M. I. Rodriguez, L. C. Lopez, V. Tapias, A. Entrena, E. Camacho, M. D. Carrion, M. A. Gallo, A. Espinosa, D. X. Tan, R. J. Reiter and D. Acuna-Castroviejo: Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem 98, 2023-33 (2006)
37. A. R. Ressmeyer, J. C. Mayo, V. Zelosko, R. M. Sainz, D. X. Tan, B. Poeggeler, I. Antolin, B. K. Zsizsik, R. J. Reiter and R. Hardeland: Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 8, 205-13 (2003)
38. R. Hardeland, C. Backhaus and A. Fadavi: Reactions of the NO redox forms NO+, &z.ast;NO and HNO (protonated NO-) with the melatonin metabolite N1-acetyl-5-methoxykynuramine. J Pineal Res 43, 382-8 (2007)
39. J. C. Mayo, R. M. Sainz, D. X. Tan, R. Hardeland, J. Leon, C. Rodriguez and R. J. Reiter: Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 165, 139-49 (2005)
40. E. R. Rios, E. T. Venancio, N. F. Rocha, D. J. Woods, S. Vasconcelos, D. Macedo, F. C. Sousa and M. M. Fonteles: Melatonin: pharmacological aspects and clinical trends. Int J Neurosci, 120, 583-90 (2010)
41. S. Cuzzocrea, B. Zingarelli, E. Gilad, P. Hake, A. L. Salzman and C. Szabo: Protective effect of melatonin in carrageenan-induced models of local inflammation: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res 23, 106-16 (1997)
42. S. Cuzzocrea, B. Zingarelli, G. Costantino and A. P. Caputi: Protective effect of melatonin in a non-septic shock model induced by zymosan in the rat. J Pineal Res 25, 24-33 (1998)
43. S. Cuzzocrea, G. Costantino, E. Mazzon, A. Micali, A. De Sarro and A. P. Caputi: Beneficial effects of melatonin in a rat model of splanchnic artery occlusion and reperfusion. J Pineal Res 28, 52-63 (2000)
44. S. Cuzzocrea, E. Mazzon, I. Serraino, V. Lepore, M. L. Terranova, A. Ciccolo and A. P. Caputi: Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 30, 1-12 (2001)
45. L. Dugo, I. Serraino, F. Fulia, A. De Sarro, A. P. Caputi and S. Cuzzocrea: Effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in an acute model of inflammation. J Pineal Res 31, 76-84 (2001)
46. S. Cuzzocrea, and R. J. Reiter: Pharmacological actions of melatonin in acute and chronic inflammation. Curr Top Med Chem 2, 153-65 (2002)
47. R. J. Reiter, D. X. Tan, L. C. Manchester, M. Pilar Terron, L. J. Flores and S. Koppisepi: Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 52, 11-28 (2007)
48. J. H. Weishaupt, C. Bartels, E. Polking, J. Dietrich, G. Rohde, B. Poeggeler, N. Mertens, S. Sperling, M. Bohn, G. Huther, A. Schneider, A. Bach, A. L. Siren, R. Hardeland, M. Bahr, K. A. Nave and H. Ehrenreich: Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41, 313-23 (2006)
49. G. Benitez-King, A. Rios, A. Martinez & F. Anton-Tay: In vitro inhibition of Ca2+/calmodulin-dependent kinase II activity by melatonin. Biochim Biophys Acta 1290, 191-6 (1996)
50. F. Anton-Tay, G. Ramirez, I. Martinez and G. Benitez-King: In vitro stimulation of protein kinase C by melatonin. Neurochem Res 23, 601-6 (1998)
51. S. M. Reppert: Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 12, 528-31 (1997)
52. M. Becker-Andre, I. Wiesenberg, N. Schaeren-Wiemers, E. Andre, M. Missbach, J. H. Saurat and C. Carlberg: Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 269, 28531-4 (1994)
53. R. Hardeland, D. P. Cardinali, V. Srinivasan, D. W. Spence, G. M. Brown and S. R. Pandi-Perumal: Melatonin-A pleiotropic, orchestrating regulator molecule. Prog Neurobiol (2010)
54. D. Pozo, S. Garcia-Maurino, J. M. Guerrero and J. R. Calvo: mRNA expression of nuclear receptor RZR/RORalpha, melatonin membrane receptor MT, and hydroxindole-O-methyltransferase in different populations of human immune cells. J Pineal Res 37, 48-54 (2004)
55. F. Radogna, P. Sestili, C. Martinelli, M. Paolillo, L. Paternoster, M. C. Albertini, A. Accorsi, G. Gualandi and L. Ghibelli: Lipoxygenase-mediated pro-radical effect of melatonin via stimulation of arachidonic acid metabolism. Toxicol Appl Pharmacol 238, 170-7 (2009)
56. O. Nosjean, M. Ferro, F. Coge, P. Beauverger, J. M. Henlin, F. Lefoulon, J. L. Fauchere, P. Delagrange, E. Canet and J. A. Boutin: Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 275, 31311-7 (2000)
57. D. X. Tan, L. C. Manchester, M. P. Terron, L. J. Flores, H. Tamura and R. J. Reiter: Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 43, 317-20 (2007)
58. I. Antolin, J. C. Mayo, R. M. Sainz, L. del Brio Mde, F. Herrera, V. Martin and C. Rodriguez: Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 943, 163-73 (2002)
59. Y. X. Shen, S. Y. Xu, W. Wei, X. L. Wang, H. Wang & X. Sun: Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid beta-peptide 25-35. J Pineal Res 32, 163-7 (2002)
60. M. T. Lin, and M. F. Beal: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-95 (2006)
61. S. M. MohanKumar, A. Campbell, M. Block and B. Veronesi: Particulate matter, oxidative stress and neurotoxicity. Neurotoxicology 29, 479-88 (2008)
62. A. M. Lin, and L. T. Ho: Melatonin suppresses iron-induced neurodegeneration in rat brain. Free Radic Biol Med 28, 904-11 (2000)
63. J. Emerit, M. Edeas and F. Bricaire: Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 58, 39-46 (2004)
64. A. Campbell, M. A. Smith, L. M. Sayre, S. C. Bondy and G. Perry: Mechanisms by which metals promote events connected to neurodegenerative diseases. Brain Res Bull 55, 125-32 (2001)
65. S. A. Andrabi, I. Sayeed, D. Siemen, G. Wolf and T. F. Horn: Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for antiapoptotic effects of melatonin. FASEB J 18, 869-71 (2004)
66. E. Kilic, U. Kilic, B. Yulug, D. M. Hermann and R. J. Reiter: Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. J Pineal Res 36, 171-6 (2004)
67. J. Leon, D. Acuna-Castroviejo, G. Escames, D. X. Tan and R. J. Reiter: Melatonin mitigates mitochondrial malfunction. J Pineal Res 38, 1-9 (2005)
68. M. E. Gegg, B. Beltran, S. Salas-Pino, J. P. Bolanos, J. B. Clark, S. Moncada and S. J. Heales: Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J Neurochem 86, 228-37 (2003)
69. M. Eddleston and L. Mucke: Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience 54, 15-36 (1993)
70. A. Minagar, P. Shapshak, R. Fujimura, R. Ownby, M. Heyes and C. Eisdorfer: The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 202, 13-23 (2002)
71. H. Y. Yun, V. L. Dawson and T. M. Dawson: Nitric oxide in health and disease of the nervous system. Mol Psychiatry, 2, 300-10 (1997)
72. E. Esposito, A. Iacono, C. Muia, C. Crisafulli, G. Mattace Raso, P. Bramanti, R. Meli and S. Cuzzocrea: Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. J Pineal Res 44, 78-87 (2008)
73. X. Wang: The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 15, 345-57 (2009)
74. R. J. Reiter, S. D. Paredes, L. C. Manchester and D. X. Tan: Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 44, 175-200 (2009)
75. C. A. Medeiros, P. F. Carvalhedo de Bruin, L. A. Lopes, M. C. Magalhaes, M. de Lourdes Seabra and V. M. de Bruin: Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 254, 459-64 (2007)
76. R. Sharma, C. R. McMillan, C. C. Tenn and L. P. Niles: Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res 1068, 230-6 (2006)
77. X. Yang, Y. Yang, Z. Fu, Y. Li, J. Feng, J. Luo, Q. Zhang, Q. Wang and Q. Tian: Melatonin ameliorates alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol (2010)
78. J. M. Olcese, C. Cao, T. Mori, M. B. Mamcarz, A. Maxwell, M. J. Runfeldt, L. Wang, C. Zhang, X. Lin, G. Zhang & G. W. Arendash: Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 47, 82-96 (2009)
79. S. Jacob, B. Poeggeler, J. H. Weishaupt, A. L. Siren, R. Hardeland, M. Bahr and H. Ehrenreich: Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res 33, 186-7 (2002)
80. E. Daglioglu, M. Serdar Dike, K. Kilinc, D. Erdogan, G. Take, F. Ergungor, O. Okay and Z. Biyikli: Neuroprotective effect of melatonin on experimental peripheral nerve injury: an electron microscopic and biochemical study. Cen Eur Neurosurg 70, 109-14 (2009)
81. T. Genovese, E. Mazzon, C. Muia, P. Bramanti, A. De Sarro and S. Cuzzocrea: Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin. J Pineal Res 38, 198-208 (2005)
82. J. E. Jan, D. Hamilton, N. Seward, D. K. Fast, R. D. Freeman and M. Laudon: Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J Pineal Res 29, 34-9 (2000)
83. M. L. Seabra, M. Bignotto, L. R. Pinto, Jr. and S. Tufik: Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 29, 193-200 (2000)
84. B. J. Kelley and R. C. Petersen: Alzheimer's disease and mild cognitive impairment. Neurol Clin 25, 577-609, (2007)
85. D. J. Selkoe: The molecular pathology of Alzheimer's disease. Neuron 6, 487-98 (1991)
86. M. A. Pappolla, R. A. Omar, K. S. Kim and N. K. Robakis: Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol 140, 621-8 (1992)
87. L. Balazs and M. Leon: Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 19, 1131-7(1994)
88. R. Pamplona, E. Dalfo, V. Ayala, M. J. Bellmunt, J. Prat, I. Ferrer and M. Portero-Otin: Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280, 21522-30 (2005)
89. Q. Liu, M. A. Smith, J. Avila, J. DeBernardis, M. Kansal, A. Takeda, X. Zhu, A. Nunomura, K. Honda, P. I. Moreira, C. R. Oliveira, M. S. Santos, S. Shimohama, G. Aliev, J. de la Torre, H. A. Ghanbari, S. L. Siedlak, P. L. Harris, L. M. Sayre and G. Perry: Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 38, 746-54 (2005)
90. D. T. Weldon, S. D. Rogers, J. R. Ghilardi, M. P. Finke, J. P. Cleary, E. O'Hare, W. P. Esler, J. E. Maggio and P. W. Mantyh: Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18, 2161-73 (1998)
91. D. J. Selkoe: Alzheimer's disease is a synaptic failure. Science 298, 789-91 (2002)
92. L. Saragoni, P. Hernandez and R. B. Maccioni: Differential association of tau with subsets of microtubules containing posttranslationally-modified tubulin variants in neuroblastoma cells. Neurochem Res 25, 59-70 (2000)
93. J. P. Brion, B. H. Anderton, M. Authelet, R. Dayanandan, K. Leroy, S. Lovestone, J. N. Octave, L. Pradier, N. Touchet and G. Tremp: Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 81-8 (2001)
94. N. Dragicevic, M. Mamcarz, Y. Zhu, R. Buzzeo, J. Tan, G. W. Arendash and P. C. Bradshaw: Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis 20, S535-50 (2010)
95. R. H. Swerdlow, J. M. Burns and S. M. Khan: The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20, S265-79 (2010)
96. R. Ozcankaya, and N. Delibas: Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J 43, 28-32 (2002)
97. F. Magri, M. Locatelli, G. Balza, G. Molla, G. Cuzzoni, M. Fioravanti, S. B. Solerte and E. Ferrari: Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging. Chronobiol Int 14, 385-96 (1997)
98. Y. H. Wu, M. G. Feenstra, J. N. Zhou, R. Y. Liu, J. S. Torano, H. J. Van Kan, D. F. Fischer, R. Ravid and D. F. Swaab: Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 88, 5898-906 (2003)
99. E. Ferrari, A. Arcaini, R. Gornati, L. Pelanconi, L. Cravello, M. Fioravanti, S. B. Solerte and F. Magri: Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 35, 1239-50 (2000)
100. J. N. Zhou, R. Y. Liu, W. Kamphorst, M. A. Hofman and D. F. Swaab: Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35, 125-30 (2003)
101. A. Rousseau, S. Petren, J. Plannthin, T. Eklundh and C. Nordin: Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. J Neural Transm 106, 883-8 (1999)
102. M. A. Pappolla, M. Sos, R. A. Omar, R. J. Bick, D. L. Hickson-Bick, R. J. Reiter, S. Efthimiopoulos and N. K. Robakis: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 17, 1683-90 (1997)
103. X. C. Li, Z. F. Wang, J. X. Zhang, Q. Wang and J. Z. Wang: Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 510, 25-30 (2005)
104. Y. Cheng, Z. Feng, Q. Z. Zhang and J. T. Zhang: Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin 27, 129-39 (2006)
105. G. Olivieri, U. Otten, F. Meier, G. Baysang, B. Dimitriades-Schmutz, F. Muller-Spahn and E. Savaskan: Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience 120, 659-65 (2003)
106. E. Crespo, M. Macias, D. Pozo, G. Escames, M. Martin, F. Vives, J. M. Guerrero and D. Acuna-Castroviejo: Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 13, 1537-46 (1999)
107. G. Escames, J. Leon, M. Macias, H. Khaldy and D. Acuna-Castroviejo: Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 17, 932-4 (2003)
108. J. J. Garcia, R. J. Reiter, J. Pie, G. G. Ortiz, J. Cabrera, R. M. Sainz and D. Acuna-Castroviejo: Role of pinoline and melatonin in stabilizing hepatic microsomal membranes against oxidative stress. J Bioenerg Biomembr 31, 609-16 (1999)
109. L. I. Brusco, M. Marquez and D. P. Cardinali: Monozygotic twins with Alzheimer's disease treated with melatonin: Case report. J Pineal Res 25, 260-3 (1998)
110. V. Srinivasan, S. R. Pandi-Perumal, G. J. Maestroni, A. I. Esquifino, R. Hardeland and D. P. Cardinali: Role of melatonin in neurodegenerative diseases. Neurotox Res 7, 293-318 (2005)
111. M. A. Pappolla, M. J. Simovich, T. Bryant-Thomas, Y. J. Chyan, B. Poeggeler, M. Dubocovich, R. Bick, G. Perry, F. Cruz-Sanchez and M. A. Smith: The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res 32, 135-42 (2002)
112. E. P. Jesudason, B. Baben, B. S. Ashok, J. G. Masilamoni, R. Kirubagaran, W. C. Jebaraj and R. Jayakumar: Anti-inflammatory effect of melatonin on A beta vaccination in mice. Mol Cell Biochem 298, 69-81 (2007)
113. M. A. Pappolla, Y. J. Chyan, B. Poeggeler, B. Frangione, G. Wilson, J. Ghiso and R. J. Reiter: An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 107, 203-31(2000)
114. M. Pappolla, P. Bozner, C. Soto, H. Shao, N. K. Robakis, M. Zagorski, B. Frangione and J. Ghiso: Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 273, 7185-8 (1998)
115. W. Song, and D. K. Lahiri: Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci 9, 75-92 (1997)
116. B. Poeggeler, L. Miravalle, M. G. Zagorski, T. Wisniewski, Y. J. Chyan, Y. Zhang, H. Shao, T. Bryant-Thomas, R. Vidal, B. Frangione, J. Ghiso and M. A. Pappolla: Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry 40, 14995-5001 (2001)
117. E. Matsubara, T. Bryant-Thomas, J. Pacheco Quinto, T. L. Henry, B. Poeggeler, D. Herbert, F. Cruz-Sanchez, Y. J. Chyan, M. A. Smith, G. Perry, M. Shoji, K. Abe, A. Leone, I. Grundke-Ikbal, G. L. Wilson, J. Ghiso, C. Williams, L. M. Refolo, M. A. Pappolla, D. G. Chain and E. Neria: Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85, 1101-8 (2003)
118. J. Quinn, D. Kulhanek, J. Nowlin, R. Jones, D. Pratico, J. Rokach and R. Stackman: Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res 1037, 209-13 (2005)
119. Z. Feng, C. Qin, Y. Chang and J. T. Zhang: Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 40, 101-9 (2006)
120. J. Zhou, S. Zhang, X. Zhao and T. Wei: Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res 45, 157-65 (2008)
121. Y. Q. Deng, G. G. Xu, P. Duan, Q. Zhang and J. Z. Wang: Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 26, 519-26 (2005)
122. Z. Feng, Y. Chang, Y. Cheng, B. L. Zhang, Z. W. Qu, C. Qin and J. T. Zhang: Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 37, 129-36 (2004)
123. Z. Feng, and J. T. Zhang: Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Biol Med 37, 1790-801 (2004)
124. Z. Feng, Y. Cheng and J. T. Zhang: Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J Pineal Res 37, 198-206 (2004)
125. C. Veneroso, M. J. Tunon, J. Gonzalez-Gallego and P. S. Collado: Melatonin reduces cardiac inflammatory injury induced by acute exercise. J Pineal Res 47, 184-91 (2009)
126. R. M. Kostrzewa and J. Segura-Aguilar: Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. a review. Neurotox Res 5, 375-83 (2003)
127. P. Brunner, N. Sozer-Topcular, R. Jockers, R. Ravid, D. Angeloni, F. Fraschini, A. Eckert, F. Muller-Spahn and E. Savaskan: Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur J Histochem 50, 311-6 (2006)
128. D. P. Cardinali, L. I. Brusco, C. Liberczuk and A. M. Furio: The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett 23, 20-3 (2002)
129. K. Asayama, H. Yamadera, T. Ito, H. Suzuki, Y. Kudo and S. Endo: Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and noncognitive functions in Alzheimer type dementia. J Nippon Med Sch 70, 334-41(2003)
130. G. Jean-Louis, F. Zizi, H. von Gizycki and H. Taub: Effects of melatonin in two individuals with Alzheimer's disease. Percept Mot Skills 87, 331-9 (1998)
131. W. Linert and G. N. Jameson: Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease. J Inorg Biochem 79, 319-26 (2000)
132. D. B. Calne: The nature of Parkinson's disease. Neurochem Int 20, 1S-3S (1992)
133. T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M. Yokochi, Y. Mizuno and N. Shimizu: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-8 (1998)
134. R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov and J. T. Greenamyre: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3, 1301-6 (2000)
135. D. Di Monte and C. P. Lawler: Mechanisms of parkinsonism: session X summary and research needs. Neurotoxicology 22, 853-4 (2001)
136. M. A. Collins and E. J. Neafsey: Potential neurotoxic "agents provocateurs" in Parkinson's disease. Neurotoxicol Teratol 24, 571-7 (2002)
137. S. Fahn and G. Cohen: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32, 804-12 (1992)
138. C. W. Olanow: Oxidation reactions in Parkinson's disease. Neurology 40, discussion 37-9 (1990)
139. Z. I. Alam, A. Jenner, S. E. Daniel, A. J. Lees, N. Cairns, C. D. Marsden, P. Jenner and B. Halliwell: Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69, 1196-203 (1997)
140. D. T. Dexter, C. J. Carter, F. R. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner and C. D. Marsden: Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52, 381-9 (1989)
141. T. L. Perry and V. W. Yong: Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67, 269-74 (1986)
142. J. Lotharius and K. L. O'Malley: The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275, 38581-8 (2000)
143. J. W. Langston, P. Ballard, J. W. Tetrud and I. Irwin: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-80 (1983)
144. W. J. Nicklas, I. Vyas and R. E. Heikkila: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36, 2503-8 (1985)
145. Y. Zhang, V. L. Dawson and T. M. Dawson: Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7, 240-50 (2000)
146. J. D. Jr. Adams, M. L. Chang and L. Klaidman: Parkinson's disease - redox mechanisms. Curr Med Chem 8, 809-14 (2001)
147. P. Hantraye, M. Varastet, M. Peschanski, D. Riche, P. Cesaro, J. C. Willer and M. Maziere: Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53, 169-78 (1993)
148. L. J. Chen, Y. Q. Gao, X. J. Li, D. H. Shen and F. Y. Sun: Melatonin protects against MPTP/MPP+ -induced mitochondrial DNA oxidative damage in vivo and in vitro. J Pineal Res 39, 34-42 (2005)
149. G. Benitez-King, G. Ramirez-Rodriguez, L. Ortiz and I. Meza: The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 3, 515-33 (2004)
150. F. Dabbeni-Sala, S. Di Santo, D. Franceschini, S. D. Skaper and P. Giusti: Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15, 164-170 (2001)
151. J. C. Mayo, R. M. Sainz, H. Uria, I. Antolin, M. M. Esteban and Rodriguez: Inhibition of cell proliferation: a mechanism likely to mediate the prevention of neuronal cell death by melatonin. J Pineal Res 25, 12-8 (1998)
152. H. A. Hanagasi, D. Ayribas, K. Baysal and M. Emre: Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease. Int J Neurosci 115, 479-93 (2005)
153. D. Alvira, M. Tajes, E. Verdaguer, D. Acuna-Castroviejo, J. Folch, A. Camins and M. Pallas: Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res 40, 251-8 (2006)
154. M. Kitazawa, S. Oddo, T. R. Yamasaki, K. N. Green and F. M. LaFerla: Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25, 8843-53 (2005)
155. R. Bordet, D. Devos, S. Brique, Y. Touitou, J. D. Guieu, C. Libersa and A. Destee: Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 26, 65-72 (2003)
156. G. Escames, D. Acuna Castroviejo and F. Vives: Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat. Neuroreport 7, 597-600 (1996)
157. E. Shamir, Y. Barak, I. Shalman, M. Laudon, N. Zisapel, R. Tarrasch, A. Elizur and R. Weizman: Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 58, 1049-52 (2001)
158. R. J. Hughes, R. L. Sack and A. J. Lewy: The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 21, 52-68 (1998)
159. G. A. Dowling, J. Mastick, E. Colling, J. H. Carter, C. M. Singer and M. J. Aminoff: Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 6, 459-66 (2005)
160. D. Dori, G. Casale, S. B. Solerte, M. Fioravanti, G. Migliorati, G. Cuzzoni and E. Ferrari: Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 21, 121-6 (1994)
161. K. Mishima, M. Okawa, T. Shimizu and Y. Hishikawa: Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab 86, 129-34 (2001)
162. C. A. Ross, and S. J. Tabrizi: Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10, 83-98 (2011)
163. F. O. Walker: Huntington's disease. Lancet 369, 218-28 (2007)
164. A. J. Tobin and E. R. Signer: Huntington's disease: the challenge for cell biologists. Trends Cell Biol 10, 531-6 (2000)
165. I. Arnulf, J. Nielsen, E. Lohmann, J. Schiefer, E. Wild, P. Jennum, E. Konofal, M. Walker, D. Oudiette, S. Tabrizi and A. Durr: Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 65, 482-8 (2008)
166. M. Bjorkqvist, E. J. Wild, J. Thiele, A. Silvestroni, R. Andre, N. Lahiri, E. Raibon, R. V. Lee, C. L. Benn, D. Soulet, A. Magnusson, B. Woodman, C. Landles, M. A. Pouladi, M. R. Hayden, A. Khalili-Shirazi, M. W. Lowdell, P. Brundin, G. P. Bates, B. R. Leavitt, T. Moller and S. J. Tabrizi: A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205, 1869-77 (2008)
167. J. M. van der Burg, M. Bjorkqvist and P. Brundin: Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 8, 765-74 (2009)
168. J. P. Vonsattel: Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115, 55-69 (2008)
169. M. DiFiglia, M. Sena-Esteves, K. Chase, E. Sapp, E. Pfister, M. Sass, J. Yoder, P. Reeves, R. K. Pandey, K. G. Rajeev, M. Manoharan, D. W. Sah, P. D. Zamore and N. Aronin: Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 104, 17204-9 (2007)
170. L. P. Rowland and N. A. Shneider: Amyotrophic lateral sclerosis. N Engl J Med 344, 1688-700 (2001)
171. R. J. Reiter: Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56, 359-84 (1998)
172. D. X. Tan, R. J. Reiter, L. C. Manchester, M. T. Yan, M. El-Sawi, R. M. Sainz, J. C. Mayo, R. Kohen, M. Allegra and R. Hardeland: Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2, 181-97 (2002)
173. N. Buscemi, B. Vandermeer, N. Hooton, R. Pandya, L. Tjosvold, L. Hartling, G. Baker, T. P. Klassen and S. Vohra: The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20, 1151-8 (2005)
174. N. Buscemi, B. Vandermeer, N. Hooton, R. Pandya, L. Tjosvold, L. Hartling, S. Vohra, T. P. Klassen and G. Baker: Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332, 385-93 (2006)
175. P. Lemoine, T. Nir, M. Laudon and N. Zisapel: Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16, 372-80 (2007)
176. A. G. Wade, I. Ford, G. Crawford, A. D. McMahon, T. Nir, M. Laudon and N. Zisapel: Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 23, 2597-605 (2007)
177. M. Gupta, Y. K. Gupta, S. Agarwal, S. Aneja, M. Kalaivani and K. Kohli: Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsia 45, 1636-9 (2004)
178. M. Gupta, Y. K. Gupta, S. Agarwal, S. Aneja and K. Kohli: A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br J Clin Pharmacol 58, 542-7 (2004)
179. P. Lissoni, M. Chilelli, S. Villa, L. Cerizza and G. Tancini: Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35, 12-5 (2003)
180. C. R. T. Jr. Vijayalaxmi, R. J. Reiter and T. S. Herman: Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20, 2575-601 (2002)
181. R. Chinery, J. A. Brockman, M. O. Peeler, Y. Shyr, R. D. Beauchamp and R. J. Coffey: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med 3, 1233-41 (1997)
182. B. Kucukakin, M. Wilhelmsen, J. Lykkesfeldt, R. J. Reiter, J. Rosenberg and I. Gogenur: No effect of melatonin to modify surgical-stress response after major vascular surgery: a randomised placebo-controlled trial. Eur J Vasc Endovasc Surg 40, 461-7 (2010)
183. B. Kucukakin, M. Klein, J. Lykkesfeldt, R. J. Reiter, J. Rosenberg and I. Gogenur: No effect of melatonin on oxidative stress after laparoscopic cholecystectomy: a randomized placebo-controlled trial. Acta Anaesthesiol Scand 54, 1121-7 (2010)
184. C. M. Forrest, G. M. Mackay, N. Stoy, T. W. Stone and L. G. Darlington: Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br J Clin Pharmacol 64, 517-26 (2007)
185. S. D. Paredes, A. Korkmaz, L. C. Manchester, D. X. Tan and R. J. Reiter: Phytomelatonin: a review. J Exp Bot 60, 57-69 (2009)